These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33079733)

  • 1. Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
    Makena MR; Nguyen TH; Koneru B; Hindle A; Chen WH; Verlekar DU; Kang MH; Reynolds CP
    Anticancer Drugs; 2021 Jan; 32(1):34-43. PubMed ID: 33079733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
    Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP
    Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
    Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
    BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
    Song MM; Makena MR; Hindle A; Koneru B; Nguyen TH; Verlekar DU; Cho H; Maurer BJ; Kang MH; Reynolds CP
    Anticancer Drugs; 2019 Feb; 30(2):117-127. PubMed ID: 30272587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
    Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
    Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
    Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
    Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
    Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
    Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.
    Chen NE; Maldonado NV; Khankaldyyan V; Shimada H; Song MM; Maurer BJ; Reynolds CP
    Mol Cancer Ther; 2016 Nov; 15(11):2653-2664. PubMed ID: 27530131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
    Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
    Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
    Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM
    Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
    Sarcar B; Kahali S; Chinnaiyan P
    J Neurooncol; 2010 Sep; 99(2):201-7. PubMed ID: 20135194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
    Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
    Zain J; O'Connor OA
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition.
    Jing B; Jin J; Xiang R; Liu M; Yang L; Tong Y; Xiao X; Lei H; Liu W; Xu H; Deng J; Zhou L; Wu Y
    Cell Death Dis; 2018 May; 9(6):589. PubMed ID: 29789603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
    Gao M; Chen G; Wang H; Xie B; Hu L; Kong Y; Yang G; Tao Y; Han Y; Wu X; Zhang Y; Dai B; Shi J
    Oncotarget; 2016 May; 7(20):29102-15. PubMed ID: 27074555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
    Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
    Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.